Evaluation of the NovaLisa™ <i>Leishmania Infantum</i> IgG ELISA in A Reference Diagnostic Laboratory in A Non-Endemic Country
Anti-<i>Leishmania</i> antibodies may be detectable in patients with leishmaniasis. Here, we compared a commercial enzyme-linked immunosorbent assay (ELISA) for the detection of anti-<i>Leishmania</i> antibodies, with an immunofluorescence antibody test (IFAT) that is no long...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-02-01
|
Series: | Antibodies |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4468/8/1/20 |
id |
doaj-26acda666b594110a62cbadd30138338 |
---|---|
record_format |
Article |
spelling |
doaj-26acda666b594110a62cbadd301383382020-11-25T01:51:36ZengMDPI AGAntibodies2073-44682019-02-01812010.3390/antib8010020antib8010020Evaluation of the NovaLisa™ <i>Leishmania Infantum</i> IgG ELISA in A Reference Diagnostic Laboratory in A Non-Endemic CountryChristen Rune Stensvold0Amalie Vang Høst1Salem Belkessa2Henrik Vedel Nielsen3Department of Bacteria, Parasites & Fungi, Statens Serum Institut, Artillerivej 5, DK–2300 Copenhagen S, DenmarkDepartment of Bacteria, Parasites & Fungi, Statens Serum Institut, Artillerivej 5, DK–2300 Copenhagen S, DenmarkDepartment of Bacteria, Parasites & Fungi, Statens Serum Institut, Artillerivej 5, DK–2300 Copenhagen S, DenmarkDepartment of Bacteria, Parasites & Fungi, Statens Serum Institut, Artillerivej 5, DK–2300 Copenhagen S, DenmarkAnti-<i>Leishmania</i> antibodies may be detectable in patients with leishmaniasis. Here, we compared a commercial enzyme-linked immunosorbent assay (ELISA) for the detection of anti-<i>Leishmania</i> antibodies, with an immunofluorescence antibody test (IFAT) that is no longer commercially available. Eighty-six serum samples from 73 patients were tested. The results obtained by the NovaLisa™ <i>Leishmania infantum</i> IgG ELISA, interpreted according to the instructions of the manufacturer, but with a modified cut-off for borderline positive values, were compared with the IFAT results that were already available. Moreover, <i>Leishmania</i> Western blot IgG results were available for 43 of the samples. The overall concordance of ELISA and IFAT was 67%. The ELISA and IFAT tests scored as 24% and 15% of the samples being positive, respectively, while 13% and 33% scored as borderline-positive, respectively. Using a Western blot (WB) as the reference, the sensitivities and specificities for the positive plus borderline-positive samples combined was 95.5% (95% confidence interval (CI), 77.2⁻99.9%) and 81.0% (95% CI, 58.1⁻94.6%) for ELISA, and 95.5% (95% CI, 77.2⁻99.9%) and 42.9% (95% CI, 21.8⁻66.0%) for IFAT, respectively. Overall, the ELISA proved to be a cost-effective alternative to the IFAT, due to its higher accuracy and specificity, and with a consequently lower number of confirmatory WB tests being required. Lastly, we also present data on the associations between seroconversion and the type of leishmaniasis.https://www.mdpi.com/2073-4468/8/1/20parasiteclinical microbiologyvector-borne diseaseleishmaniasisdiagnosisdiagnostic methodsmolecular epidemiology |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Christen Rune Stensvold Amalie Vang Høst Salem Belkessa Henrik Vedel Nielsen |
spellingShingle |
Christen Rune Stensvold Amalie Vang Høst Salem Belkessa Henrik Vedel Nielsen Evaluation of the NovaLisa™ <i>Leishmania Infantum</i> IgG ELISA in A Reference Diagnostic Laboratory in A Non-Endemic Country Antibodies parasite clinical microbiology vector-borne disease leishmaniasis diagnosis diagnostic methods molecular epidemiology |
author_facet |
Christen Rune Stensvold Amalie Vang Høst Salem Belkessa Henrik Vedel Nielsen |
author_sort |
Christen Rune Stensvold |
title |
Evaluation of the NovaLisa™ <i>Leishmania Infantum</i> IgG ELISA in A Reference Diagnostic Laboratory in A Non-Endemic Country |
title_short |
Evaluation of the NovaLisa™ <i>Leishmania Infantum</i> IgG ELISA in A Reference Diagnostic Laboratory in A Non-Endemic Country |
title_full |
Evaluation of the NovaLisa™ <i>Leishmania Infantum</i> IgG ELISA in A Reference Diagnostic Laboratory in A Non-Endemic Country |
title_fullStr |
Evaluation of the NovaLisa™ <i>Leishmania Infantum</i> IgG ELISA in A Reference Diagnostic Laboratory in A Non-Endemic Country |
title_full_unstemmed |
Evaluation of the NovaLisa™ <i>Leishmania Infantum</i> IgG ELISA in A Reference Diagnostic Laboratory in A Non-Endemic Country |
title_sort |
evaluation of the novalisa™ <i>leishmania infantum</i> igg elisa in a reference diagnostic laboratory in a non-endemic country |
publisher |
MDPI AG |
series |
Antibodies |
issn |
2073-4468 |
publishDate |
2019-02-01 |
description |
Anti-<i>Leishmania</i> antibodies may be detectable in patients with leishmaniasis. Here, we compared a commercial enzyme-linked immunosorbent assay (ELISA) for the detection of anti-<i>Leishmania</i> antibodies, with an immunofluorescence antibody test (IFAT) that is no longer commercially available. Eighty-six serum samples from 73 patients were tested. The results obtained by the NovaLisa™ <i>Leishmania infantum</i> IgG ELISA, interpreted according to the instructions of the manufacturer, but with a modified cut-off for borderline positive values, were compared with the IFAT results that were already available. Moreover, <i>Leishmania</i> Western blot IgG results were available for 43 of the samples. The overall concordance of ELISA and IFAT was 67%. The ELISA and IFAT tests scored as 24% and 15% of the samples being positive, respectively, while 13% and 33% scored as borderline-positive, respectively. Using a Western blot (WB) as the reference, the sensitivities and specificities for the positive plus borderline-positive samples combined was 95.5% (95% confidence interval (CI), 77.2⁻99.9%) and 81.0% (95% CI, 58.1⁻94.6%) for ELISA, and 95.5% (95% CI, 77.2⁻99.9%) and 42.9% (95% CI, 21.8⁻66.0%) for IFAT, respectively. Overall, the ELISA proved to be a cost-effective alternative to the IFAT, due to its higher accuracy and specificity, and with a consequently lower number of confirmatory WB tests being required. Lastly, we also present data on the associations between seroconversion and the type of leishmaniasis. |
topic |
parasite clinical microbiology vector-borne disease leishmaniasis diagnosis diagnostic methods molecular epidemiology |
url |
https://www.mdpi.com/2073-4468/8/1/20 |
work_keys_str_mv |
AT christenrunestensvold evaluationofthenovalisaileishmaniainfantumiiggelisainareferencediagnosticlaboratoryinanonendemiccountry AT amalievanghøst evaluationofthenovalisaileishmaniainfantumiiggelisainareferencediagnosticlaboratoryinanonendemiccountry AT salembelkessa evaluationofthenovalisaileishmaniainfantumiiggelisainareferencediagnosticlaboratoryinanonendemiccountry AT henrikvedelnielsen evaluationofthenovalisaileishmaniainfantumiiggelisainareferencediagnosticlaboratoryinanonendemiccountry |
_version_ |
1724997451938529280 |